NEW PORT RICHEY, Fla., Jan. 29, 2019 (SEND2PRESS NEWSWIRE) — The C. Diff Foundation Board of Directors announced today that the 2019 “Above and Beyond” Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.
“We are very proud to recognize Ms. Jones with our “Above and Beyond” award,” said C. Diff Foundation Founder and President, Nancy Caralla. “Lee’s dedication to the entire C. diff community of patients, family members, and physicians hasn’t wavered since the founding of Rebiotix in 2011. She is a true example of what can happen when focusing on patient well-being drives new approaches to healthcare.”
The award will be presented by the Foundation’s Vice President, Scott Battles, and Treasurer Angelo Ortiz at the Rebiotix facility.
“It’s an honor to receive this award from the C. Diff Foundation,” said Ms. Jones. “The purpose of starting Rebiotix was to bring the power of the microbiome to the clinic in a scientifically sound, quality-controlled way to help patients. We stand with the Foundation in believing that patient well-being should be at the core of all that we do, from clinical trials to exploring new scientific landscapes within the microbiome space.”
About the C Diff Foundation:
The C Diff Foundation is a non-profit, 501(c)(3) organization established in 2012. It is comprised of 100% volunteering professionals dedicated to supporting public health through education and advocacy for C. difficile infection prevention, treatments, environmental safety and support world-wide. The Foundation’s CEO and founder is a nurse inspired to create the foundation after witnessing the loss of her father to CDI, as well as suffering from the infection herself. The C Diff Foundation members, with their volunteer patient advocates, successfully “raise C. diff awareness” locally and in over fifty-six (56) countries and host a U.S. nation-wide hotline (1-844-FOR-CDIF) to support healthcare providers, patients and families through the difficulties of a C. diff infection. Learn more: https://cdifffoundation.org/
About Rebiotix Inc.:
Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.
Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit https://www.rebiotix.com/
Twitter: @cdiffFoundation #CdiffInfection #Clostridiumdifficile @Rebiotix
MEDIA ONLY CONTACT:
(not for print or online)
*LOGO link for media: Send2Press.com/300dpi/18-0316s2p-cdiff-fdn-300dpi.jpg
News Source: C Diff Foundation